| Document Date: 2011-02-23 12:59:48
Open Document File Size: 84,00 KBShare Result on Facebook
City Basel / / Company Advanced HPV Diagnostics / Roche Molecular Systems / Roche Group / Chugai Pharmaceutical / Genentech / / Country Switzerland / Japan / United States / / Currency CHF / / Facility University of Virginia Health System / National Cancer Institute / / IndustryTerm pharmaceuticals / diabetes management / diagnostic tools / research-focused healthcare / valid tool / / MedicalCondition tissue-based cancer / cervical cancers / cancer / disease / HPV / cervical cancer / diabetes / HPV infection / Cervical Cancer Persistent infection / cervical disease / Cervical Cancer ATHENA / inflammation / / Organization National Cancer Institute / World Health Organization / U.S. Food and Drug Administration / University of Virginia Health System / / Person Mark H. Stoler / Paul Brown / / Position Director of Surgical Pathology and Cytopathology / leader / Professor / Head / / PublishedMedium the American Journal / / Technology Genotyping / genotype / / URL www.roche.com / /
SocialTag |
Media Release Pleasanton / XX February, 2011 Pivotal Study Validates Roche’s cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer